The Effect of Polybrene on an aPTT-based Lupus Anticoagulant Test in the Plasma of Patients Receiving Unfractionated Heparin
Abstract
Objective: Heparins can interfere with lupus anticoagulant (LA) testing, especially when the detection assays do not contain a heparin neutralizer. In this study we evaluated whether hexadimethrine bromide commonly known as polybrene was able to neutralize the effects of unfractionated heparin (UFH) on activated partial thromboplastin time (aPTT)-based LA determination.
Material and Methods: The influence of polybrene on the aPTT-based LA testing results of 14 patients receiving UFH therapy was studied. Measurements were performed using Dade Actin FSL (aPTT-LA screen) and Dade Actin FS (aPTT-LA confirm) reagents on a Sysmex CS-1600 analyzer. The aPTT-LA screen/confirm ratios before and after the polybrene treatments were compared.
Results: The UFH treatment affected the aPTT-LA screen/confirm ratio in four patterns, 1) no coagulation (NC code), 2) false positive, 3) false low, and 4) unchanged interpretation. After adding polybrene in the patient plasmas, the aPTT-LA screen/confirm ratios returned nearly to baseline without false positive or negative results.
Conclusion: The best practice for LA testing should be done outside anticoagulant therapies, but if necessary, the tests can be performed by adding the proper concentration of polybrene.
Keywords
Full Text:
PDFReferences
Kojima T. Targeted gene disruption of natural anticoagulant proteins in mice. Int J Hematol 2002;76(Suppl 2):36-9.
Langdown J, Johnson DJ, Baglin TP, Huntington JA. Allosteric activation of antithrombin critically depends upon hinge region extension. J Biol Chem 2004;279:47288-97.
Valenstein PN, Walsh MK, Meier F, College of American Pathologists. Heparin monitoring and patient safety: a College of American Pathologists Q-Probes study of 3431 patients at 140 institutions. Arch Pathol Lab Med 2004;128:397-402.
Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-7.
Coene KLM, van der Graaf F, van de Kerkhof D. Protocolled redefinition of the therapeutic range for unfractionated heparin: lost in translation? Clin Appl Thromb Hemost 2018;24:164-71.
Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016;41:165-86.
Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56.
Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.
Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014;40:163-71.
Moore GW. Commonalities and contrasts in recent guidelines for lupus anticoagulant detection. Int J Lab Hematol 2014; 36:364-73.
Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020;18:2828-39.
Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, British Committee for Standards in Hematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47-58.
CLSI. Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI document H60-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
Sangle NA, Rodgers GM, Smock KJ. Prevalence of heparin in samples submitted for lupus anticoagulant testing. Lab Hematol 2011;17:6-11.
Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995;86:617-23.
Grann VR, Homewood K, Golden W. Polybrene neutralization as a rapid means of monitoring blood heparin levels. Am J Clin Pathol 1972;58:26-32.
Kikura M, Lee MK, Levy JH. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. Anesth Analg 1996;83:223-7.
Godal HC. A comparison of two heparin-neutralizing agents: protamine and polybrene. Scand J Clin Lab Invest 1960;12:446- 57.
Tientadakul P, Kongkan C, Chinswangwatanakul W. Use of an automated coagulation analyzer to perform heparin neutralization with polybrene in blood samples for routine coagulation testing: practical, rapid, and inexpensive. Arch Pathol Lab Med 2013;137:1641-7.
Opartkiattikul N, Tientadakul P, Wongtiraporn W. Evaluation of the activated partial thromboplastin time (aPTT) sensitivity to unfractionated heparin using three commercial reagents: implication for therapeutic range. Siriraj Med J 2005;57:536-9.
Lawrie AS, Kitchen S, Efthymiou M, Mackie IJ, Machin SJ. Determination of APTT factor sensitivity-the misguiding guideline. Int J Lab Hematol 2014;35:652–7.
Jacobsen EM, Trettenes EJ, Wisløff F, Abildgaard U. Detection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene. Thromb J 2006;4. doi: 10.1186/1477-9560-4-3.
Cumming AM, Jones GR, Wensley RT, Cundall RB: In vitro neutralization of heparin in plasma prior to the activated partial thromboplastin time test: an assessment of four heparin antagonists and two anion exchange resins. Thromb Res 1986,41:43-56.
Antovic A, Norberg EM, Berndtsson M, Rasmuson A, Malmström RE, Skeppholm M, et al. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. Thromb Haemost 2017;117:1700-4.
De Kesel PMM, Devreese KMJ. The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results? Res Pract Thromb Haemost 2020;4:161-8.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.